The BH3-only protein, PUMA, is involved in oxaliplatin-induced apoptosis in colon cancer cells

Biochemical Pharmacology

Volumn 71, Issue 11, 2006, Pages 1540-1550

  Wang, Xinying ^a,b   Li, Ming ^b   Wang, Jide ^a   Yeung, Chung Man ^b   Zhang, Hongquan ^a   Kung, Hsiang fu ^c   Jiang, Bo ^a   Chia mi Lin, Marie ^b  

^a FIRST MILITARY MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Apoptosis; Colon cancer; ERK; Oxaliplatin; p53; PUMA

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; BH3 PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 3; OXALIPLATIN; P53 UPREGULATED MODULATOR OF APOPTOSIS PROTEIN; PROTEIN BCL 2; PROTEIN P53; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME INACTIVATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLAVONOIDS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 8; MITOGEN-ACTIVATED PROTEIN KINASE 9; ORGANOPLATINUM COMPOUNDS; PROTO-ONCOGENE PROTEINS; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33646480058     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2006.02.011     Document Type: Article

References (40)

1. Di Francesco A.M., Ruggiero A., and Riccardi R. Cellular and molecular aspects of drugs of the future: oxaliplatin. Cell Mol Life Sci 59 (2002) 1914-1927
2. Jerremalm E., Eksborg S., and Ehrsson H. Hydrolysis of oxaliplatinevaluation of the acid dissociation constant for the oxalato monodentate complex. J Pharm Sci 92 (2003) 436-438
3. Spingler B., Whittington D.A., and Lippard S.J. A crystal structure of an oxaliplatin 1, 2-d (GpG) intrastrand cross-link in a DNA dodecamer duplex. Inorg Chem 40 (2001) 5596-5602
4. Raymond E., Faivre S., Chaney S., Woynarowski J., and Cvitkovic E. Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther 1 (2002) 227-235
5. Harrap K.R. cis-Diamminedichloroplatinum (II)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 37 (1996) 463-471
6. Li G.M. The role of mismatch repair in DNA damage-induced apoptosis. Oncol Res 11 (1999) 393-400
7. Ormerod M.G., O'Neill C., Robertson D., Kelland L.R., and Harrap K.R. cis Diamminedichloro-platinum (II)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 37 (1996) 463-471
8. Lowe S.W., and Lin A.W. Apoptosis in cancer. Carcinogenesis 21 (2000) 485-495
9. Johnstone R.W., Ruefli A.A., and Lowe S.W. Apoptosis: a link between cancer genetics and chemotherapy. Cell 108 (2002) 153-164
10. Nakano K., and Vousden K.H. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 7 (2001) 683-694
11. Yu J., Zhang L., Hwang P.M., Kinzler K.W., and Vogelstein B. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 7 (2001) 673-682
12. Puthalakath H., and Strasser A. Keeping killers on a tight leash: transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins. Cell Death Differ 9 (2002) 505-512
13. Yamaguchi H., Chen J.D., Bhalla K., and Wang H.G. Regulation of Bax activation and apoptotic response to microtubule-damaging agents by p53 transcription-dependent and -independent pathways. J Biol Chem 279 (2004) 39431-39437
14. Schuler M., and Green D.R. Mechanisms of p53-dependent apoptosis. Biochem Soc Trans 29 (2001) 684-687
15. DeHaan R.D., Yazlovitshaya E.M., and Persons D.L. Regulation of p53 target gene expression by cisplatin-induced extracellular signal-regulated kinase. Cancer Chemother Pharmacol 48 (2001) 383-388
16. Futami T., Miyagishi M., and Taira K. Identification of a network involved in thapsigargin-induced apoptosis using a library of siRNA-expression vectors. J Biol Chem 280 (2005) 826-831
17. Chang L., and Karin M. Mammalian MAP kinase signalling cascades. Nature 410 (2001) 37-40
18. Widmann C., Gibson S., Jarpe M.B., and Johnson G.L. Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol Rev 79 (1999) 143-180
19. Xia Z., Dickens M., Raingeaud J., Davis R.J., and Greenberg M.E. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270 (1995) 1326-1331
20. p38. Diabetes 52 (2003) 1073-1080
21. Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., et al. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 48 (1988) 589-601
22. Komarov P.G., Komarova E.A., Kondratov R.V., Christov-Tselkov K., Coon J.S., Chernov M.V., et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 285 (1999) 1733-1737
23. Raymond E., Faivre S., Woynarowski J.M., and Chaney S.G. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 25 (1998) 4-12
24. Giannakakou P., Nakano M., Nicolaou K.C., O'Brate A., Yu J., Blagosklonny M.V., et al. Enhanced microtubule-dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics. Proc Natl Acad Sci USA 99 (2002) 10855-10860
25. Middelburg R., de Haas R.R., Dekker H., Kerkhoven R.M., Pohlmann P.R., Fuentes-Alburo A., et al. Induction of p53 up-regulated modulator of apoptosis messenger RNA by chemotherapeutic treatment of locally advanced breast cancer. Clin Cancer Res 11 (2005) 1863-1869
26. Arango D., Wilson A.J., Shi Q., Corner G.A., Aranes M.J., Nicholas C., et al. Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Br J Cancer 91 (2004) 1931-1946
27. Yu J., Wang Z., Kinzler K.W., Vogelstein B., and Zhang L. PUMA mediates the apoptotic response to p53 in colorectal cancer cells. Proc Natl Acad Sci USA 100 (2003) 1931-1936
28. Jeffers J., Parganas E., Lee Y., Yang C., Wang J., Brennan J., et al. Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell 4 (2003) 321-328
29. Ito H., Kanzawa T., Miyoshi T., Hirohata S., Kyo S., Iwamaru A., et al. Therapeutic efficacy of PUMA for malignant glioma cells regardless of p53 status. Hum Gene Ther 16 (2005) 685-698
30. Hershko T., and Ginsberg D. Up-regulation of Bcl-2 homology 3 (BH3)-only proteins by E2F1 mediates apoptosis. J Biol Chem 279 (2004) 8627-8634
31. Walton M.I., Wilson S.C., Hardcastle I.R., Mirza A.R., and Workman P. An evaluation of the ability of pifithrin-alpha and -beta to inhibit p53 function in two wild-type p53 human tumor cell lines. Mol Cancer Ther 4 (2005) 1369-1377
32. Melino G., Bernassola F., Ranalli M., et al. p73 Induces apoptosis via PUMA transactivation and Bax mitochondrial translocation. J Biol Chem 279 (2004) 8076-8083
33. Vasilevskaya I.A., Rakitina T.V., and O'Dwyer P.J. Quantitative effects on c-Jun N-terminal protein kinase signaling determine synergistic interaction of cisplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines. Mol Pharmacol 65 (2004) 235-243
34. Persons D.L., Yazlovitskaya E.M., Cui W., and Pelling J.C. Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin. Clin Cancer Res 5 (1999) 1007-1014
35. Woessmann W., Chen X.B., and Borkhardt A. Ras-mediated activation of ERK by cisplatin induces cell death independently of p53 in osteosarcoma and neuroblastoma cell lines. Cancer Chemother Pharmacol 50 (2002) 397-404
36. Rakitina T.V., Vasilevskaya I.A., and O'Dwyer P.J. Additive interaction of oxaliplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines results from inhibition of nuclear factor B signaling. Cancer Res 63 (2003) 8600-8605
37. Brummelkamp T.R., Bernards R., and Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 296 (2002) 550-553
38. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell 88 (1997) 323-331
39. Ko L.J., and Prives C. p53: puzzle and paradigm. Genes Dev 10 (1996) 1054-1072
40. Vogelstein B., Lane D., and Levine A.J. Surfing the p53 network. Nature 408 (2000) 307-310